After the screening, we selected a CHRM4 candidate inhibitor, ceritinib, to test its pharmacological effects on prostate cancer cells compared to known CHRM4 inhibitors (LY2033298 and PD102807) (Table 1). This evidence concerns the gene CHRM4 and prostate carcinoma.